You are here

Home

Analysis

Explanation: What is the ‘delta plus’ variant of the coronavirus?

Fri, 2021-10-22 10:02 — mike kraft
What is the 'delta plus' variant of the coronavirus? What is the “delta plus” variant? It’s a relative of the delta variant, identified by British scientists last month. Because it isn't a variant of interest or concern, it has not yet been officially named after a letter of the Greek alphabet, like the other worrisome variants. AP NEWS

What is the “delta plus” variant?

It’s a relative of the delta variant, identified by British scientists last month.

Country / Region Tags: 
Global
UK - London
United Kingdom
United States
General Topic Tags: 
COVID-19
Health
Mutations
Pandemics
Science
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Pfizer says COVID-19 vaccine more than 90% effective in kids

Fri, 2021-10-22 09:39 — mike kraft
Pfizer says COVID-19 vaccine more than 90% effective in kids Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group. AP NEWS
Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Contagion
Data
Disease
Health
Pandemics
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Pfizer, BioNTech say COVID-19 booster shot showed high 95.6% efficacy in large study

Thu, 2021-10-21 17:52 — mike kraft
Pfizer, BioNTech say COVID-19 booster shot showed high efficacy in large study A booster dose of the COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE restored efficacy to 95.6% against the virus, including the Delta variant, data released by the companies from a large study showed on Thursday. Reuters Reuters
Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Contagion
Data
Disease
Health
Pandemics
Research
Vaccinations
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Pfizer says testing shows booster restores full protection against COVID-19

Thu, 2021-10-21 08:37 — mike kraft
Pfizer says testing shows booster restores full protection against Pfizer and BioNTech announced on Thursday that a booster Jordan Williams TheHill

Pfizer and BioNTech announced on Thursday that a booster shot of their coronavirus vaccine restores full protection against COVID-19.

Country / Region Tags: 
Germany
Global
United States
General Topic Tags: 
COVID-19
Contagion
Data
Disease
Health
Science
Vaccinations
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Persons infected with COVID reinfections are likely to get reinfected within one or two years, models suggest propose

Wed, 2021-10-20 20:02 — mike kraft
COVID reinfections likely within one or two... Nature - Estimates based on viral evolution forecast a 50% risk 17 months after a first infection without measures such as masking and vaccination. Peeples, Lynne nature
Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Contagion
Data
Disease
Health
Medical Testing
Pandemics
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Only very older and already very sick vaccinated persons are likely to die if infected with COVID-19--Italian study

Wed, 2021-10-20 19:18 — mike kraft
Only very old and sick die of COVID if vaccinated, Italian study shows People vaccinated against COVID-19 are highly unlikely to die of the disease unless very old and already badly ill before getting it, a study in Italy showed on Wednesday. Reuters Reuters
Country / Region Tags: 
Global
Italy
General Topic Tags: 
COVID-19
Contagion
Data
Demographics
Disease
Health
Pandemics
Vaccinations
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

Study exaimines out-of-pocket costs for Covid-19 hospitalizations, even with waivers

Wed, 2021-10-20 18:10 — mike kraft
Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020 This cross-sectional study assesses out-of-pocket spending by privately insured and Medicare Advantage patients for COVD-19 hospitalizations in 2020.
Country / Region Tags: 
United States
General Topic Tags: 
COVID-19
Data
Health
Hospitals
Public Health
Research
Economics
Problem, Solution, SitRep, or ?: 
Analysis

Children with mild COVID-19 may not develop antibodies; oral vaccine shows promise in monkey study

Wed, 2021-10-20 17:41 — mike kraft
Children with mild COVID-19 may not develop antibodies; oral vaccine booster shows promise in monkey study The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review. Nancy Lapid Reuters
Country / Region Tags: 
Australia
Global
United States
General Topic Tags: 
COVID-19
Contagion
Data
Disease
Health
Medical Testing
Pandemics
Research
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report

CDC tool analyizes breakthrough cases for Pfizer, Moderna, J&J

Wed, 2021-10-20 10:06 — mike kraft
Chances of getting COVID-19 after a vaccine: CDC tool shows breakthrough cases for Pfizer, Moderna, J&J A new CDC tool visualizes just how well the vaccines work against breakthrough cases and death compared to being unvaccinated. Michael Grothaus Fast Company
Country / Region Tags: 
Global
United States
General Topic Tags: 
COVID-19
Contagion
Data
Disease
Health
Medical Testing
Pandemics
Research
Science
Vaccinations
Problem, Solution, SitRep, or ?: 
Analysis

The Most Common Places COVID Is Spreading Right Now (And Where It's Not)

Tue, 2021-10-19 10:23 — mike kraft
The Most Common Places COVID Is Spreading Right Now (And Where It's Not) Curious what activities may be associated with higher COVID-19 transmission? Here's what data suggests. Catherine Pearson YahooNews
Country / Region Tags: 
United States
General Topic Tags: 
COVID-19
Contagion
Disease
Health
Masks
Pandemics
Policy
Research
Social behavior
Community
Public Attitudes
Public Health
Problem, Solution, SitRep, or ?: 
Analysis

Pages

Subscribe to Analysis
howdy folks
Page loaded in 0.690 seconds.